FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 江蘇恒瑞醫藥股份有限公司 呈交日期： 2025年9月30日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | 600276 | 說明 | A股（於上海證券交易所上市） | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件 ...

格隆汇9月30日丨恒瑞医药(01276.HK)发布公告，2025年9月30日耗资人民币69.45万元回购1万股A股， 回购价格每股69.45-69.45元。 ...

智通财经APP讯，恒瑞医药(01276)发布公告，该公司于2025年9月30日斥资69.45万元人民币回购1万股A 股，每股回购价格为69.45元人民币。 ...

恒瑞医药（600276）(01276)发布公告，该公司于2025年9月30日斥资69.45万元人民币回购1万股A股， 每股回购价格为69.45元人民币。 ...

Market Overview - The Shanghai Composite Index rose by 0.52% on September 30, with 19 out of 28 sectors experiencing gains, led by the non-ferrous metals and defense industries, which increased by 3.22% and 2.59% respectively [1] - The pharmaceutical and biological industry saw an increase of 1.40% [1] - The sectors with the largest declines were telecommunications and non-bank financials, which fell by 1.83% and 1.14% respectively [1] Capital Flow Analysis - The main capital outflow from the two markets totaled 32.303 billion yuan, with only four sectors seeing net inflows [1] - The defense industry had the highest net inflow of 2.059 billion yuan, while the non-ferrous metals sector followed with a net inflow of 1.984 billion yuan [1] - The non-bank financial sector experienced the largest net outflow, totaling 11.405 billion yuan, followed by telecommunications with a net outflow of 5.936 billion yuan [1] Pharmaceutical and Biological Sector Performance - The pharmaceutical and biological sector had a net inflow of 984 million yuan, with 310 out of 475 stocks rising, including two hitting the daily limit [2] - The top three stocks by net inflow were WuXi AppTec with 1.113 billion yuan, followed by Hengrui Medicine and Yong'an Pharmaceutical with 431 million yuan and 134 million yuan respectively [2] - Nine stocks in this sector saw net outflows exceeding 50 million yuan, with C Jianfa Zhi leading at 896.727 million yuan [3] Top Gainers in Pharmaceutical Sector - WuXi AppTec increased by 6.42% with a turnover rate of 2.86% and a main capital flow of 1.112 billion yuan [2] - Hengrui Medicine rose by 3.40% with a turnover rate of 0.91% and a main capital flow of 431 million yuan [2] - Yong'an Pharmaceutical saw a rise of 6.92% with a turnover rate of 16.56% and a main capital flow of 134 million yuan [2] Top Losers in Pharmaceutical Sector - C Jianfa Zhi decreased by 15.04% with a turnover rate of 52.49% and a main capital flow of -896.727 million yuan [3] - Xiangrikui rose by 2.00% but had a net outflow of 854.806 million yuan [3] - Jilin Aodong fell by 1.91% with a net outflow of 797.945 million yuan [3]

Group 1 - The chemical pharmaceutical sector increased by 1.63% on September 30, with Mengke Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3882.78, up 0.52%, while the Shenzhen Component Index closed at 13526.51, up 0.35% [1] - Notable gainers in the chemical pharmaceutical sector included Mengke Pharmaceutical, which rose by 8.45% to a closing price of 9.11, and Yong'an Pharmaceutical, which increased by 6.92% to 18.08 [1] Group 2 - The chemical pharmaceutical sector saw a net inflow of 256 million yuan from main funds, while retail investors experienced a net outflow of 320 million yuan [2] - Key stocks with significant main fund inflows included Heng Rui Pharmaceutical with 37.4 million yuan and Yong'an Pharmaceutical with 134 million yuan [3] - Conversely, stocks like ST Suwu and ST Fuhua experienced declines of 5.00% and 4.97%, respectively, indicating a mixed performance within the sector [2]

Core Viewpoint - Heng Rui Medicine (01276) experienced a significant stock price increase, with a rise of over 4% at the close, and a current price of HKD 87.95, with a trading volume of HKD 217 million [1] Group 1: Clinical Trials and Approvals - Heng Rui Medicine announced the approval to conduct clinical trials for SHR-7787 injection, SHR-4849 injection, Bevacizumab injection, and Atezolizumab injection [1] Group 2: Licensing Agreement - The company granted Glenmark, an Indian pharmaceutical company, exclusive rights to develop and commercialize its HER2 antibody-drug conjugate, Trastuzumab deruxtecan, in global non-core markets, receiving an upfront payment of USD 18 million and potential milestone payments exceeding USD 1 billion [1] Group 3: Market Rights and Financial Impact - Nomura's report indicates that Heng Rui retains development and commercialization rights for Trastuzumab deruxtecan in major pharmaceutical markets including Greater China, the US, Canada, Europe, and Japan, suggesting that the upfront payment will have a minimal financial impact, but the overall milestone payment scale could be substantial [1] - The collaboration with Glenmark is expected to help unlock the commercial potential of the product, and retaining rights in key markets provides opportunities for larger-scale partnerships in the future [1]

Core Viewpoint - Heng Rui Medicine (600276)(01276) experienced a significant stock price increase, with a rise of over 4% at the close, and currently trading at 87.95 HKD with a transaction volume of 217 million HKD. The company announced the approval for clinical trials of several injection products, indicating a positive development in its product pipeline [1]. Group 1: Clinical Trials and Product Development - Heng Rui Medicine announced the approval for clinical trials of SHR-7787 injection, SHR-4849 injection, Bevacizumab injection, and Atezolizumab injection, showcasing its ongoing commitment to expanding its product offerings [1]. - The company granted exclusive rights to Indian pharmaceutical company Glenmark for the development and commercialization of its HER2 antibody-drug conjugate, Rukang Trastuzumab, in global non-core markets, receiving an upfront payment of 18 million USD and potential milestone payments exceeding 1 billion USD [1]. Group 2: Financial Impact and Market Strategy - Nomura's research report indicates that the upfront payment is not expected to have a significant impact on the company's finances, but the overall scale of milestone payments could be substantial [1]. - The retention of development and commercialization rights for Rukang Trastuzumab in major pharmaceutical markets such as Greater China, the US, Canada, Europe, and Japan is anticipated to provide opportunities for larger-scale collaborations with other potential partners in the future [1].

Company Overview - Jiangsu Hengrui Medicine Co., Ltd. is primarily engaged in the research, production, and sales of pharmaceuticals, focusing on oncology and covering various research areas including kinase inhibitors, antibody-drug conjugates (ADC), tumor immunology, hormone receptor regulation, DNA repair, and supportive therapies [2] - The company's product portfolio includes anti-tumor drugs, analgesics, and contrast agents, applicable in various fields such as autoimmune diseases, metabolic diseases, cardiovascular diseases, infectious diseases, respiratory diseases, hematological diseases, pain management, neurological diseases, ophthalmology, and nephrology [2] - The main revenue composition is as follows: oncology 52.12%, neuroscience 15.33%, others (supplementary) 10.63%, contrast agents 9.82%, metabolic and cardiovascular 6.25%, others 3.07%, immunology and respiratory system 2.78% [2] Financial Performance - As of June 30, 2025, Hengrui Medicine achieved a revenue of 15.76 billion yuan, representing a year-on-year growth of 15.88%, and a net profit attributable to shareholders of 4.45 billion yuan, with a year-on-year increase of 29.67% [3] - The company has distributed a total of 9.30 billion yuan in dividends since its A-share listing, with 3.57 billion yuan distributed over the past three years [3] Stock Performance - On September 30, Hengrui Medicine's stock price increased by 2.11%, reaching 70.66 yuan per share, with a trading volume of 1.846 billion yuan and a turnover rate of 0.41%, resulting in a total market capitalization of 468.985 billion yuan [1] - Year-to-date, the stock price has risen by 54.62%, with a 1.38% increase over the last five trading days, a 2.60% increase over the last twenty days, and a 32.32% increase over the last sixty days [1] - The net inflow of main funds was 169 million yuan, with significant buying and selling activities recorded [1]

Core Insights - The report emphasizes that the commercialization of AI applications is approaching a critical turning point, with a focus on domestic computing power and rapidly advancing application verticals [6][7][8] - The demand for AI applications is reflected in the significant increase in Tokens consumption, indicating a rapid expansion of AI application needs across various sectors such as AI programming, AI multimodal, AI advertising, AI education, and AI healthcare [7][8] - The report highlights the strong performance of the overseas computing power chain, with a 255% increase since April 9, 2025, while domestic computing power, particularly the Huawei chain, has seen a more modest increase of 71% [9] Market Performance - The Shanghai Composite Index closed at 3862.53, up 0.90%, while the Shenzhen Component Index rose by 2.05% to 13479.43 [3] - The performance of various industry indices shows that non-bank financials increased by 3.84%, and metals by 3.78%, while coal and oil sectors experienced declines [4] Industry Focus - The report identifies key investment opportunities in the domestic computing power and AI application sectors, particularly those related to Huawei's computing power and software chains, which are expected to yield favorable performance in the near term [9] - The AI application business model is transitioning from concept validation to revenue generation, with a clear need for established overseas business models to guide domestic market development [7][8]